Posted On: 01/24/2013 5:10:54 AM
Post# of 72446
Sunitinib
Sunitinib (marketed as Sutent by Pfizer , and previously known as SU11248 ) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib -resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. [1]
(0)
(0)
